Nucala 100 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FAZJU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,893
Award facts
- Contract value 100% obligated
- $1,892.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $1,892.90 by the Defense Logistics Agency on July 28, 2025, for the supply of Nucala 100 mg/mL syringes. This firm fixed-price delivery order, which is expected to be completed by July 29, 2025, was issued without a set-aside designation. The award represents a specific purchase order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency, valued at $499.999 billion and extending through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide.
Nucala (mepolizumab) is a biologic injection used in the treatment of eosinophilic asthma and other eosinophil-mediated conditions. This delivery order fulfills the Defense Logistics Agency's immediate pharmaceutical supply requirements for military health facilities. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing contracts for specialty medications, biologics, and medical consumables across diverse therapeutic categories. The company's continued engagement with the Defense Logistics Agency underscores its reliability as a distributor of branded and generic prescription drugs to Department of Defense healthcare systems across the nation.
Quick answers
Who was awarded contract SPE2DB25FAZJU?
SPE2DB25FAZJU was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 28, 2025.
How much is contract SPE2DB25FAZJU worth?
The government has obligated $1,893 on SPE2DB25FAZJU.
Is contract SPE2DB25FAZJU an order under another contract?
Yes. SPE2DB25FAZJU is a delivery order under SPE2DB24D9222, an indefinite delivery contract.
Was contract SPE2DB25FAZJU competed?
The extent of competition for SPE2DB25FAZJU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award